|Medicxi||Co-founder and Partner||Suisse|
How to create a European seed capital market?
Prior to co-founding medicxi, Michèle was a partner at Index Ventures for 10 years, having joined the firm in 2006. During that time she invested and continues to serve on the boards of a number of Index Life Sciences portfolio companies including Epsilon 3 Bio, Minerva Neuroscience (Nasdaq: NERV), LinguaFlex, Encare, Gadeta, and Human Antibody Factory. She was also a Director at OncoEthix (Sold to Merck Pharmaceuticals) and Aegerion (Nasdaq: AEGR).
Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/Gencell/Aventis International and Serono International.
She currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN). She also sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord. She advises the Robertson Therapeutic Development Fund at the Rockfeller University in New York City.
Michèle earned an MD from Paris-Ouest University.